<DOC>
	<DOCNO>NCT01711645</DOCNO>
	<brief_summary>Monitoring immune response longevity serum milk Tdap administration postpartum woman . The clinical trial involve woman ( age 18 - 45 year ) deliver full-term infant ( great equal 37 complete week gestation ) Vanderbilt University Medical Center . The enrollment period fifteen month . The duration two year observation .</brief_summary>
	<brief_title>Tdap Vaccine Post-Partum Women</brief_title>
	<detailed_description>This single site , prospective study involve one intervention , receipt single 0.5 mL intramuscular ( IM ) dose Adacel ( Tetanus toxoid , reduce diphtheria toxoid acellular Pertussis ) vaccine , among 55 healthy post partum woman . The purpose study examine immune response subsequent decline serum breast milk antibody titer two year observation . The clinical trial involve woman ( age 18 - 45 year ) deliver full-term infant ( great equal 37 complete week gestation ) Vanderbilt University Medical Center . One particular population Vanderbilt target `` centering prenatal care group '' breastfeed rate high 75 percent hospital discharge maintain 20 percent 6 month . The enrollment period fifteen month . The subject , staff assess subject , laboratory personnel aware receipt vaccine . Since single vaccine product utilized , blind need subject staff .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum phosphate</mesh_term>
	<criteria>Healthy , postpartum woman determine medical history age 18 45 year age inclusive . Women 14 day postpartum delivery fullterm infant . Fullterm define estimate gestational age great equal 37 complete week pregnancy determine menstrual dating concordant ultrasound finding per ACOG bulletin # 101 ) . Provide write informed consent prior initiation study procedure . Available entire study period . Able understand complete relevant study procedure study participation ( woman ultimately limited ability breast feed enrollment exclude study ) . Prior receipt tetanus diphtheriacontaining vaccine within two year enrollment . Prior receipt tetanus diphtheria toxoid acellular pertussis vaccine within two year enrollment . Known suspected impairment immunologic function . Febrile illness within last 24 hour oral temperature &gt; /= 100.4 degree F ( &gt; /= 38 degree C ) time enrollment . History document tetanus , diphtheria , pertussis disease within precede 5 year . History allergic adverse reaction diphtheria , tetanus , pertussis vaccine . Receipt steroid , immunoglobulin , blood products/transfusion within past six month exclude Rh immunoglobulin ( Rhogam™ Rhophylac™ ) . Is enrolled plan enroll another clinical trial investigational product participate study ( observational study allow ) . Known active infection HIV , hepatitis B , hepatitis C. History alcohol drug abuse last 5 year . Any condition , opinion investigator , may pose health risk subject interfere evaluation study objective . Any woman health condition currently take glucocorticoid , i.e. , oral , parenteral , highdose inhaled steroid , immunosuppressive cytotoxic drug . Sensitive latex , base package insert Progressive unstable neurologic condition , base package insert . Receipt influenza vaccine concomitantly administer 42 day follow Adacel , base package insert .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Tetanus , Diptheria toxoid , Acellular , Pertussis , Tdap , Adacel® , postpartum , woman</keyword>
</DOC>